2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Ulf Landmesser, Marcus Flather et al.|European Heart Journal|2023Cited by 2.3k
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y. Ho, Eugene Braunwald, Sharlene M. Day et al.|Nature Medicine|2021Cited by 132
Partial oral treatment of endocarditisKasper Iversen, Henning Bundgaard, Nis Høst et al.|American Heart Journal|2013Cited by 45
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G. Ireland, Carolyn Y. Ho, Danielle S. Burstein et al.|Circulation Heart Failure|2024Cited by 6
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin‐Cristian Topriceanu, Carolyn Y. Ho, Christoffer Rasmus Vissing et al.|Circulation Heart Failure|2025Cited by 3